A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas

被引：46
|
作者：
Feugier, Pierre [1 ,2 ]
机构：
[1] Ctr Hosp Univ Nancy, Serv Hematol, F-54511 Vandoeuvre Les Nancy, France
[2] Univ Lorraine, INSERM 954, Unite NGERE, F-54000 Nancy, France
来源：
FUTURE ONCOLOGY | 2015年 / 11卷 / 09期
关键词：
CD20; monoclonal antibody; non-Hodgkin's lymphoma; STEM-CELL TRANSPLANTATION; DETUDE-DES-LYMPHOMES; HIGH-DOSE CHEMOTHERAPY; PROSPECTIVE RANDOMIZED-TRIAL; PROGRESSION-FREE SURVIVAL; RELAPSED FOLLICULAR LYMPHOMA; BENDAMUSTINE PLUS RITUXIMAB; 3-WEEKLY CHOP CHEMOTHERAPY; EVENT-FREE SURVIVAL; HIGH TUMOR BURDEN;
D O I：
10.2217/fon.15.57
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Rituximab is a type I anti-CD20 monoclonal antibody, which stabilizes CD20 on lipid rafts, promoting antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. It is the first targeted therapy used in B-cell malignancies and has revolutionized their treatment, without excess of toxicity. In combination with chemotherapy, it has significantly improved response rates and progression-free survival and, for some of them, overall survival of patients with diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma. Moreover, it has been shown to improve progression-free survival in maintenance in follicular lymphoma as well as mantle cell lymphoma. Improvement of its efficacy includes exploration of resistance mechanisms, pharmacokinetics parameters, role of vitamin D and evaluation of subcutaneous route, among others.
引用
收藏
页码：1327 / 1342
页数：16
相关论文
共 50 条
  • [31] Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation
    Tsai, DE
    Moore, HCF
    Hardy, CL
    Porter, DL
    Loh, EY
    Vaughn, DJ
    Luger, S
    Schuster, SJ
    Stadtmauer, EA
    BONE MARROW TRANSPLANTATION, 1999, 24 (05) : 521 - 526
  • [32] Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody
    Tsai, DE
    Maillard, I
    Schuster, SJ
    Nasta, SD
    Porter, DL
    Klumpp, TR
    Goldenberg, DM
    Luger, SM
    Alavi, A
    Sharkey, RM
    Hartzell, KB
    Stadtmauer, EA
    CLINICAL LYMPHOMA, 2003, 4 (01): : 56 - 59
  • [33] Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma
    Negrea, George O.
    Elstrom, Rebecca
    Allen, Steven L.
    Rai, Kanti R.
    Abbasi, Rashid M.
    Farber, Charles M.
    Teoh, Nick
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (04): : 567 - 573
  • [34] Anti-CD20 monoclonal antibody (Rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement
    Hänel, M
    Fiedler, F
    Thorns, C
    ONKOLOGIE, 2001, 24 (05): : 491 - 494
  • [35] Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy
    Tuccori, Marco
    Focosi, Daniele
    Blandizzi, Corrado
    Pelosini, Matteo
    Montagnani, Sabrina
    Maggi, Fabrizio
    Pistello, Mauro
    Antonioli, Luca
    Fornai, Matteo
    Pepe, Pasquale
    Rossi, Giuseppe
    Petrini, Mario
    ONCOLOGIST, 2010, 15 (11) : 1214 - 1219
  • [36] Real Time Analysis of Binding between Rituximab (Anti-CD20 Antibody) and B Lymphoma Cells
    Tan, Liang
    Lin, Peiling
    Chisti, Mohammad M.
    Rehman, Abdul
    Zeng, Xiangqun
    ANALYTICAL CHEMISTRY, 2013, 85 (18) : 8543 - 8551
  • [37] Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
    Sharkey, Robert M.
    Karacay, Habibe
    Johnson, Christine R.
    Litwin, Samuel
    Rossi, Edmund A.
    McBride, Williarn J.
    Chang, Chien-Hsing
    Goldenbero, David M.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (03) : 444 - 453
  • [38] Treatment of indolent non-Hodgkin's Lymphomas
    Moreno Nogueira, J. A.
    Casas Fernandez de Tejerina, A.
    Moreno Rey, C.
    REVISTA CLINICA ESPANOLA, 2009, 209 (02): : 82 - 87
  • [39] Treatment of non-Hodgkin's lymphomas in the elderly
    Späth-Schwalbe, E
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2001, 34 (04): : 263 - 268
  • [40] Ofatumumab in the treatment of non-Hodgkin's lymphomas
    Karlin, Lionel
    Coiffier, Bertrand
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (07) : 1085 - 1091
12345